Bupropion sustained-release for the treatment of dysthymic disorder: An open-label study

Journal of Clinical Psychopharmacology

Volumn 21, Issue 3, 2001, Pages 325-329

  Hellerstein, David J ^a,b   Batchelder, Sarai ^a   Kreditor, David ^a   Fedak, Michael ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; PLACEBO;

ADULT; AGED; ALCOHOL ABUSE; ANOREXIA; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; MALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RESTLESSNESS; SUBSTANCE ABUSE; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREMOR;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRIEF PSYCHIATRIC RATING SCALE; BUPROPION; CHI-SQUARE DISTRIBUTION; DELAYED-ACTION PREPARATIONS; DYSTHYMIC DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 0035023182     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200106000-00012     Document Type: Article

References (24)

1. Keller MB, Hanks DL. Course and natural history of chronic depression. In: Kocsis JH, Klein DN, eds. Diagnosis and treatment of chronic depression. New York: Guilford Press, 1995:58-72.
2. Howland RH. Pharmacotherapy of dysthymia: a review. J Clin Psychopharmacol 1991;11:83-92.
3. Lapierre YD. Pharmacological therapy of dysthymia. Acta Psychiatr Scand 1994;89:42-8.
4. Lima MS, Moncrieff J. A comparison of drugs versus placebo for the treatment of dysthymia; a systematic review. Cochrane Library, issue 4. Oxford, UK: Update Software, 2000.
5. Dunner DL, Hendrickson HE, Bea C, et al. Venlafaxine in dysthymic disorder. J Clin Psychiatry 1997;58:528-31.
6. Hellerstein, DJ, Batchelder ST, Little SAS, et al. Venlafaxine in the treatment of dysthymia: an open-label study. J Clin Psychiatry 1999;60:845-9.
7. Settle EC. Bupropion sustained release: side effect profile. J Clin Psychiatry 1998;59[suppl 4]:32-6.
8. Davidson JRT, Connor KM. Bupropion sustained release: a therapeutic overview. J Clin Psychiatry 1998;59[suppl 4]:25-31.
9. Dewan MJ, Anand VS. Evaluating the tolerability of the newer antidepressants. J Nerv Ment Dis 1999;187:96-101.
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;25:56-62.
11. Mason BJ, Kocsis JH, Leon AC, et al. Measurement of severity and treatment response in dysthymia. Psychiatr Ann 1993;23:625-31.
12. Guy W, ed. ECDEU assessment manual for psychopharmacology. Publication ADM 76-338. Rockville, MD: U.S. Department of Health, Education, and Welfare, 1976.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994:32-33.
14. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
15. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci 1974;19:1-15.
16. Thase ME, Fava M, Halbreich U, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia Arch Gen Psychiatry 1996;53:777-84.
17. Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM-III-R, patient version (SCID-P). New York: New York State Psychiatric Institute, Biometrics Research Department, 1988.
18. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse and recurrence. Arch Gen Psychiatry 1991;48:851-5.
19. Hellerstein DJ, Yanowitch P, Rosenthal J, et al. A randomized double-blind study of fluoxetine versus placebo in treatment of dysthymia. Am J Psychiatry 1993;150:1169-75.
20. Ravindran AV, Charbonneau Y, Zaharia MD, et al. Efficacy and tolerability of Venlafaxine in the treatment of primary dysthymia. J Psychiatry Neurosci 1998;23:288-92.
21. Marin DB, Kocsis JH, Frances AJ, et al. Desipramine for the treatment of "pure" dysthymia versus "double" depression. Am J Psychiatry 1994;151:1079-80.
22. Hayford KE, Patten CA, Rummans TA, et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999;174:173-8.
23. Riggs PD, Leon SL, Mikulich SK, et al. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 1998;37: 1271-8.
24. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000;157:1445-52.